Fundraising Fox
Crossfire Oncology
1 known investors
Find your way into Crossfire Oncology
Sign up to see every warm intro you have to Crossfire Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Crossfire Oncology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Crossfire Oncology develops kinase inhibitors, degraders, and degrader antibody conjugates targeting cancer and other cellular proliferation disorders using proprietary EPriL chemistry. The company serves oncology markets with a pipeline including BAL0891, a clinical-stage dual TTK/PLK1 inhibitor.
Investors · 1
Frequently asked questions
- What does Crossfire Oncology do?
- Crossfire Oncology develops kinase inhibitors, degraders, and degrader antibody conjugates targeting cancer and other cellular proliferation disorders using proprietary EPriL chemistry. The company serves oncology markets with a pipeline including BAL0891, a clinical-stage dual TTK/PLK1 inhibitor.
- Who are Crossfire Oncology's investors?
- Crossfire Oncology's investors include BOM.